The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Ji, Fei ^a   Fu, Shun Jun ^b   Shen, Shun Li ^a   Zhang, Long Juan ^a   Cao, Qing Hua ^a   Li, Shao Qiang ^a   Peng, Bao Gang ^a   Liang, Li Jian ^a   Hua, Yun Peng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

Author keywords

Biomarkers; Embryonic liver fodrin; Hepatocellular carcinoma; Prognosis; Transforming growth factor

Indexed keywords

ADAPTOR PROTEIN; EMBRYONIC LIVER FODRIN; HEPATITIS B SURFACE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; CARRIER PROTEIN; FODRIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; TUMOR RECURRENCE; TUMOR VOLUME; CANCER GRADING; CARCINOMA, HEPATOCELLULAR; FOLLOW UP; GENE EXPRESSION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR BURDEN; YOUNG ADULT;

EID: 84924856743     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1127-y     Document Type: Article

References (37)

1. EI-serag HB, Rudolph KL. Hepatocellular carcinoma:epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-76.
2. Tang ZY. Hepatocellular carcinoma-cause, treatment, and metastasis. World J Gastroenterol. 2001;7:445-54.
3. World Health Organization: The world health report 2006. http://www.who.int/whr/2006/en/
4. Ng KK, Lo CM, Liu CL, Poon RT, Chan SC, Fan ST. Survival analysis of patients with transplantable recurrent hepatocellular carcinoma: implications for salvage liver transplant. Arch Surg. 2008;143:68-74.
5. Kim DY, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, et al. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology. 2007;72:52-7.
6. Zarzynska JM. Two Faces of TGF-Beta1 in Breast Cancer. Mediators Inflamm. 2014;2014:141747.
7. Heldin CH, Landström M, Moustakas A. Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelialmesenchymal transition. Curr Opin Cell Biol. 2009;21:166-76.
8. Ikushima H, Miyazono K. Biology of transforming growth factor-β signaling. Curr Pharm Biotechnol. 2011;12:2099-107.
9. Moses H, Barcellos-Hoff MH. TGF-β biology in mammary development and breast cancer. Cold Spring Harb Perspect Biol. 2011;3:a003277.
10. Parvani JG, Taylor MA, Schiemann WP. Noncanonical TGF-β signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia. 2011;16:127-46.
11. Katz LH, Li Y, Chen JS, Muñoz NM, Majumdar A, Chen J, et al. Targeting TGF-β signaling in cancer. Expert Opin Ther Targets. 2013;17:743-60.
12. Bierie B, Moses HL. Transforming growth factor beta (TGF-β) and inflammation in cancer. Cytokine Growth Factor Rev. 2010;21:49-59.
13. Kajdaniuk D, Marek B, Borgiel-Marek H, Kos-Kudła B. Transforming growth factorβ1 (TGFβ1) in physiology and pathology. Endokrynol Pol. 2013;64:384-96.
14. Zu X, Zhang Q, Gao R, Liu J, Zhong J, Wen G. Transforming growth factor-β signaling in tumor initiation, progression and therapy in breast cancer: an update. Cell Tissue Res. 2012;347:73-84.
15. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci. 2010;55:2744-55.
16. Hua YP, Li SQ, Lai JM, Liang LJ, Peng BG, Liang HZ, et al. Changes in TGF-β/Smads signaling pathway in rats with chemical hepatocarcinogenesis. J South Med Univ. 2008;28:1848-52.
17. Baek HJ, Lim SC, Kitisin K, Joqunoori W, Tang Y, Marshall MB, et al. Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology. 2008;48:1128-37.
18. Thenappan A, Shukla V, Abdul Khalek FJ, Thenappan A, Shukla V, Abdul Khalek FJ, et al. Loss of transforming growth factor β adaptor protein β-2 spectrin leads to delayed liver regeneration in mice. Hepatology. 2011;53:1641-50.
19. Wang Z, Song Y, Tu W, He X, Lin J, Liu F. β-2 spectrin is involved in hepatocyte proliferation through the interaction of TGFβ/Smad and PI3K/AKT signaling. Liver Int. 2012;32:1103-11.
20. Tang Y, Katuri V, Srinivasan R, Foqt F, Redman R, Anand G, et al. Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. Cancer Res. 2005;65:4228-37.
21. Mishra L, Katuri V, Evans S. The role of PRAJA and ELF in TGF-beta signaling and gastric cancer. Cancer Biol Ther. 2005;4:694-9.
22. Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, et al. Progenitor/ stem cells give rise to liver cancer due to aberrant TGF- beta and IL-6 signaling. Proc Natl Acad Sci U S A. 2008;105:2445-50.
23. Kim SS, Shetty K, Katuri V, Kitisin K, Baek HJ, Tang Y, et al. TGF-beta signaling pathway inactivation and cell cycle deregulation in the development of gastric cancer: role of the beta-spectrin, ELF. Biochem Biophys Res Commun. 2006;344:1216-23.
24. Kitisin K, Ganesan N, Tang Y, Joqunoori W, Volpe EA, Kim SS, et al. Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene. 2007;26:7103-10.
25. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-2.
26. Sobin LH, Wittekind C. UICC (International Union against Cancer) TNM classification of malignant tumors. 6th ed. New York: John Wiley; 2002. p. 1-264.
27. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
28. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9:139-48.
29. Wu F, Liu SY, Tao YM, Ou DP, Fang F. Decreased expression of methyl methansulfonate and UV sensitive gene clone 81 is related to poor prognosis of patients with hepatocellular carcinoma. Cancer. 2008;112:2002-10.
30. Wu F, Yang LY, Li YF, Ou DP, Chen DP, Fan C. Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology. 2009;50:1839-50.
31. Tripsianis G, Papadopoulou E, Romanidis K, Katotomichelakis M, Anagnostopoulos K, Kontomanolis E, et al. Overall Survival and Clinicopathological Characteristics of Patients with Breast Cancer in Relation to the Expression Pattern of HER-2, IL-6, TNF-α and TGF-β1. Asian Pac J Cancer Prev. 2013;14:6813-20.
32. de Kruijf EM, Dekker TJ, Hawinkels LJ, Putter H, Smit VT, Kroep JR, et al. The prognostic role of TGF-β signaling pathway in breast cancer patients. Ann Oncol. 2013;24:384-90.
33. Song S, Maru DM, Ajani JA, Chan CH, Honjo S, Lin HK, et al. Loss of TGF-β adaptor β2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer Res. 2013;73:2159-69.
34. Baek HJ, Pishvaian MJ, Tang Y, Kim TH, Yang S, Zouhairi ME, et al. Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer. Hepatology. 2011;53:1676-84.
35. Katuri V, Tang Y, Marshall B, Rashid A, Jogunoori W, Volpe EA, et al. Inactivation of ELF/TGF-beta signaling in human gastrointestinal cancer. Oncogene. 2005;24:8012-24.
36. Baek HJ, Kim SS, da Silva FM, Volpe EA, Evans S, Mishra B, et al. Inactivation of TGF-beta signaling in lung cancer results in increased CDK4 activity that can be rescued by ELF. Biochem Biophys Res Commun. 2006;346:1150-7.
37. Li SX, Tang GS, Zhou DX, Pan YF, Tan YX, Zhang J, et al. Prognostic significance of cytoskeleton- associated membrane protein 4 and its palmitoyl acyltransferase DHHC2 in hepatocellular carcinoma. Cancer. 2014;120:1520-31.